ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

venetoclax

Also written as “Venetoclax”, “ABT-199” and “ABT-199 (Main Cohort)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 3 companies.

Drug pageVenetoclax: every studyAll 486 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 22, 202167 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only5312 open or runningphase 4since Nov 22, 2021Apr 1, 2011Nov 2026phase 2 · NCT04895436
Hoffmann-La Rocheits history only131 open or runningphase 3since Dec 4, 2013Aug 10, 2012none ahead
Oncotherapeutics11 open or runningphase 2since Aug 11, 2023Aug 11, 2023none ahead

Also a collaborator on its studies: Johnson & Johnson, Baili-Bio (Chengdu) Pharmaceutical, Roche-Genentech, Merck, Sumitomo Pharma and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Oncotherapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT06115135 · 39 planned · United States

TargetBeta

BCL2 →read by rule
“Apoptosis regulator Bcl-2 inhibitor”ChEMBL 37, by rule

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
lacutoclaxruleLupeng Pharmaceuticalphase 24
surzetoclaxAbbViephase 23
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12
FXS0683Fosun Pharmaphase 11

Studies

The one study Oncotherapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06115135Multiple Myeloma · United States2RecruitingApr 30, 202639

How it is read

Names in the registry

  • “Venetoclax”, 66 entries
  • “ABT-199”, 9 entries
  • “venetoclax”, 6 entries
  • “ABT-199 (Main Cohort)”, 1 entry
  • “ABT-199 (Safety Expansion Cohort)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.